Table 3. The five best models to construct a monogram in the training set.
| Variables | Categories | HR | 95% CI | P |
|---|---|---|---|---|
| Model 1 | ||||
| Overall survival (C-index =0.684) | ||||
| PS | 1 (vs. 0) | 1.65 | 1.40–1.95 | <0.01 |
| ≥2 (vs. 0) | 4.09 | 3.24–5.18 | <0.01 | |
| Prior gastrectomy | Yes (vs. no) | 0.72 | 0.63–0.84 | <0.01 |
| Histological type | Intestinal (vs. diffuse) | 0.89 | 0.75–1.05 | 0.15 |
| HER2 status | Positive (vs. negative) | 0.74 | 0.60–0.92 | 0.01 |
| ALP | ≥ ULN (vs. <ULN) | 1.74 | 1.46–2.07 | <0.01 |
| Progression free survival (C-index =0.641) | ||||
| PS | 1 (vs. 0) | 1.37 | 1.16–1.61 | <0.01 |
| ≥2 (vs. 0) | 3.21 | 2.56–4.04 | <0.01 | |
| Prior gastrectomy | Yes (vs. no) | 0.88 | 0.77–1.05 | 0.17 |
| HER2 status | Positive (vs. negative) | 0.78 | 0.70–1.07 | 0.17 |
| Number of metastatic sites | ≥2 (vs. 1) | 1.22 | 1.04–1.43 | 0.01 |
| LDH | ≥ ULN (vs. < ULN) | 1.39 | 1.17–1.66 | <0.01 |
| Model 2 | ||||
| Overall survival (C-index =0.683) | ||||
| PS | 1 (vs. 0) | 1.65 | 1.40–1.95 | <0.01 |
| ≥2 (vs. 0) | 4.16 | 3.30–5.25 | <0.01 | |
| Prior gastrectomy | Yes (vs. no) | 0.77 | 0.66–0.90 | <0.01 |
| HER2 status | Positive (vs. negative) | 0.68 | 0.55–0.83 | <0.01 |
| Number of metastatic sites | ≥2 (vs. 1) | 1.23 | 1.05–1.43 | 0.01 |
| ALP | ≥ ULN (vs. < ULN) | 1.64 | 1.38–1.96 | <0.01 |
| Progression free survival (C-index =0.639) | ||||
| PS | 1 (vs. 0) | 1.42 | 1.20–1.67 | <0.01 |
| ≥2 (vs. 0) | 3.56 | 2.82–4.49 | <0.01 | |
| Prior Gastrectomy | Yes (vs. no) | 0.85 | 0.74–0.99 | 0.03 |
| HER2 status | Positive (vs. negative) | 0.85 | 0.69–1.02 | 0.12 |
| Liver metastasis | Yes (vs. no) | 1.4 | 1.18–1.67 | <0.01 |
| LDH | ≥ ULN (vs. < ULN) | 1.3 | 1.08–1.55 | 0.01 |
| Model 3 | ||||
| Overall survival (C-index =0.684) | ||||
| PS | 1 (vs. 0) | 1.66 | 1.41–1.96 | <0.01 |
| ≥2 (vs. 0) | 4.21 | 3.33–5.31 | <0.01 | |
| Prior gastrectomy | Yes (vs. no) | 0.72 | 0.62–0.83 | <0.01 |
| HER2 status | Positive (vs. negative) | 0.71 | 0.58–0.87 | <0.01 |
| Bone metastasis | Yes (vs. no) | 1 | 0.64–1.56 | 0.99 |
| ALP | ≥ ULN (vs. < ULN) | 1.71 | 1.43–2.04 | <0.01 |
| Progression free survival (C-index =0.641) | ||||
| PS | 1 (vs. 0) | 1.43 | 1.16–1.60 | <0.01 |
| ≥2 (vs. 0) | 3.47 | 2.50–3.94 | <0.01 | |
| HER2 status | Positive (vs. negative) | 0.84 | 0.68–1.03 | 0.09 |
| Number of metastatic sites | ≥2 (vs. 1) | 1.17 | 1.00–1.37 | 0.05 |
| Liver metastasis | Yes (vs. no) | 1.33 | 1.11–1.60 | <0.01 |
| LDH | ≥ ULN (vs. < ULN) | 1.3 | 1.09–1.56 | <0.01 |
| Model 4 | ||||
| Overall survival (C-index =0.688) | ||||
| PS | 1 (vs. 0) | 1.65 | 1.40–1.95 | <0.01 |
| ≥2 (vs. 0) | 4.23 | 3.35–5.34 | <0.01 | |
| Prior gastrectomy | Yes (vs. no) | 0.75 | 0.64–0.86 | <0.01 |
| HER2 status | Positive (vs. negative) | 0.68 | 0.44–0.83 | <0.01 |
| ALP | ≥ ULN (vs. < ULN) | 1.49 | 1.24–1.80 | <0.01 |
| LDH | ≥ ULN (vs. < ULN) | 1.39 | 1.16–1.68 | <0.01 |
| Progression free survival (C-index =0.643) | ||||
| PS | 1 (vs. 0) | 1.38 | 1.17–1.62 | <0.01 |
| ≥2 (vs. 0) | 3.12 | 2.48–3.93 | <0.01 | |
| HER2 status | Positive (vs. negative) | 0.84 | 0.72–1.00 | 0.05 |
| Number of metastatic sites | ≥2 (vs. 1) | 1.24 | 1.07–1.44 | <0.01 |
| ALP | ≥ ULN (vs. < ULN) | 1.3 | 1.08–1.58 | 0.01 |
| LDH | ≥ ULN (vs. < ULN) | 1.27 | 1.05–1.54 | 0.01 |
| Model 5 | ||||
| Overall survival (C-index =0.687) | ||||
| PS | 1 (vs. 0) | 1.68 | 1.43–1.98 | <0.01 |
| ≥2 (vs. 0) | 4.21 | 3.33–5.32 | <0.01 | |
| HER2 status | Positive (vs. negative) | 0.65 | 0.53–0.79 | <0.01 |
| Number of metastatic sites | ≥2 (vs. 1) | 1.31 | 1.13–1.51 | <0.01 |
| ALP | ≥ ULN (vs. < ULN) | 1.4 | 1.16–1.70 | <0.01 |
| LDH | ≥ ULN (vs. < ULN) | 1.42 | 1.18–1.72 | <0.01 |
| Progression free survival (C-index =0.643) | ||||
| PS | 1 (vs. 0) | 1.43 | 1.17–1.61 | <0.01 |
| ≥2 (vs. 0) | 3.47 | 2.45–3.86 | <0.01 | |
| HER2 status | Positive (vs. negative) | 0.87 | 0.71–1.08 | 0.2 |
| Liver metastasis | Yes (vs. no) | 1.14 | 1.14–1.63 | <0.01 |
| ALP | ≥ ULN (vs. < ULN) | 1.26 | 1.03–1.53 | 0.02 |
| LDH | ≥ ULN (vs. < ULN) | 1.22 | 1.00–1.47 | 0.05 |
ALP, alkaline phosphatase; HER2, human epidermal growth factor receptor type 2; LDH, lactate dehydrogenase; PS, performance status; ULN, upper limit of normal.